REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Boron Containing Doai Boron Containing DoaiBoron Containing Doai patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.01/04/07 - 20070004677 - Linear urea mimics antagonists of p2y1 receptor useful in the treatment of thrombotic condition or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, B, W, and R6 are as defined herein. These compounds are selective inhibitors of the human P2Y1 receptor which can be used as medicaments. ... 01/04/07 - 20070004676 - Methods of using [3.2.0] heterocyclic compounds and analogs thereof Disclosed are methods of treating cancer comprising administering to the animal, a therapeutically effective amount of a heterocyclic compound of Formula VI. The animal is a mammal, preferably a human or a rodent. ... 12/07/06 - 20060276435 - Fibroblast activation protein inhibitor compounds and methods Amino terminus-blocked peptide boronate compounds of Formulas I and II are useful for inhibiting Fibroblast Activation Protein (FAP) and other proteases, and for treating disorders mediated by FAP. Methods of using the amino terminus blocked peptide boronate compounds, and stereoisomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, ... 11/30/06 - 20060270629 - Methanocarba cycloalkyl nucleoside analogues The present invention provides novel nucleoside and nucleotide derivatives that are useful agonist or antagonists of P1 and P2 receptors. For example, the present invention provides a compound of formula A-M, wherein A is modified adenine or uracil and M is a constrained cycloalkyl group. The adenine or uracil is ... 11/23/06 - 20060264401 - Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-iv The present invention is directed to pyrrolidinylaminoacetyl pyrrolidine boronic acid compounds that display selective, potent dipeptidyl peptidase IV inhibitory activity. These compounds are useful for the treatment of disorders that can be regulated or normalized via inhibition of DPP-IV including those characterized by impaired glycemic control such as Diabetes Mellitus ... 11/23/06 - 20060264400 - Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-iv The present invention is directed to pyrrolidinylaminoacetyl pyrrolidine boronic acid compounds that display selective, potent dipeptidyl peptidase IV inhibitory activity. These compounds are useful for the treatment of disorders that can be regulated or normalized via inhibition of DPP-IV including those characterized by impaired glycemic control such as Diabetes Mellitus ... 11/16/06 - 20060258622 - Methods of and compositions for reducing neuronal cell death Methods and compositions involving a class of boron-protected phenylphosphine agents having increased cell permeability and having improved chemical stability for treating or for preventing neuronal cell death-related diseases or conditions in a human or a non-human animal. ... 11/16/06 - 20060258621 - Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-iv The present invention is directed to pyrrolidinylaminoacetyl pyrrolidine boronic acid compounds that display selective, potent dipeptidyl peptidase IV (DPP-IV) inhibitory activity. These compounds are useful for the treatment of disorders that can be regulated or normalized via inhibition of DPP-IV including those characterized by impaired glycemic control such as Diabetes ... 11/02/06 - 20060247209 - N-halogenated amino acids, n,n-dihalogenated amino acids and derivatives; compositions and methods of using them The present invention relates to active bactericidal, antibacterial, anti-infective, antimicrobial, sporicidal, disinfectant, antifungal and antiviral compounds and compositions and to new uses of these compositions in therapy. This specification also describes methods of use for the new compounds and compositions. The specification further describes methods for preparing these compounds. ... 10/19/06 - 20060234981 - Boron-containing small molecules This invention relates to compounds useful for treating fungal infections, more specifically topical treatment of onychomycosis and/or cutaneous fungal infections. This invention is directed to compounds that are active against fungi and have properties that allow the compound, when placed in contact with a patient, to reach the particular part ... 09/28/06 - 20060217348 - Pyrazolo[1,5-a] pyridines and medicines containing the same [wherein R1 represents methoxy, ethyl, methylthio, etc., R2, R3 and R4 each represent hydrogen, a halogen, etc., R5 and R6 each represent —X5—X6—X7 (wherein X5 represents a single bond or —CO—, X6 represents a single bond, —NR3a, etc. and X7 and R3a each represent hydrogen, C1-10 alkyl, etc.), and Ar ... 09/28/06 - 20060217347 - Topical formulations of borinic acid antibiotics and their methods of use Disclosed are topical formulations, for example, creams, gels, or lotions, of borinic acid antibiotic compounds active against acne vulgaris or secondarily infected skin conditions. ... 08/03/06 - 20060172971 - Protection against and treatment of hearing loss The present invention provides a method for protecting against or treating hearing loss in a subject. This method involves administering an effective amount of a protein tyrosine kinase inhibitor to the subject to protect against or to treat hearing loss. ... 06/22/06 - 20060135478 - Boronated metal-phthalocyanines, process for their preparation, pharmaceutical compositions comprising them and use thereof The present invention relates to meta 1-phthalocyanines bearing at least a group containing boron isotopes 11B or 10B, covalently bound to the peripheral positions of meta 1-phthalocyanine nucleus; moreover it refers to the processes for their preparation, the pharmaceutical compositions comprising them and their use for the treatment of neoplastic ... 06/15/06 - 20060128664 - Aryl boronic acids for treating obesity R1a is —H, alkyl, substituted alkyl phenyl or substituted phenyl. Also disclosed is a method of treating obesity in a subject by administering an effective amount of a compound represented by Structural Formula (I) and a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier or diluent. ... 06/15/06 - 20060128663 - Aryl boronate functionalized polymers for treating obesity Ar in Structural Formulas (I) and (II) is substituted or unsubstituted; and each Z is —O—, —NH— or —S— and is independently selected. Pharmaceutically acceptable salts of the polymer are also included. The aryl boronate ester, boronamide or boronate thioester can be cleaved to release the corresponding aryl boronic acid. ... 06/15/06 - 20060128662 - Novel compounds for treatment of obesity are provided which are useful in the treatment of obesity. ... 05/18/06 - 20060105995 - Tafi inhibitors and their use to treat pulmonary fibrosis The invention relates to TAFI inhibitors and their use to treat pulmonary fibrosis. ... 05/04/06 - 20060094693 - Methods and compositions for treating glucose-associated conditions, metabolic syndrome, dyslipidemias and other conditions The invention relates, in part, to of Glu-boroPro containing compounds and methods of use thereof in the prevention or management of conditions that are associated with impaired glucose tolerance such as diabetes. The invention also relates to compositions of Glu-boroPro containing compounds and methods of use thereof in the prevention ... 04/13/06 - 20060079484 - Phosphinyloxy, oxime and carboxylic acid derivatives which are useful as carboxypeptidase u inhibitors which compounds inhibit carboxypeptidase U and thus can be used in the prevention and treatment of diseases associated with carboxypeptidase U. In further aspects, the invention relates to compounds of the invention for use in therapy; to processes for preparation of such new compounds; to pharmaceutical compositions containing at least ... 03/02/06 - 20060046978 - Novel compounds that inhibit dipeptidyl peptidase (dpp-iv) and neprilysin (nep) and/or angiotensin converting enzyme (ace) This invention relates to novel compounds, compositions containing the compounds, that inhibit dipeptidyl peptidase (especially DPP-IV) and neprilysin (NEP, neutral endopeptidase) as well as dipeptidyl peptidase (especially DPP-IV) and angiotensin converting enzyme (ACE) and/or dipeptidyl Peptidase (especially DPP-IV) and vasopeptidases (especially ACE and NEP). These compounds and pharmaceutical compositions thereof ... 02/23/06 - 20060040898 - Novel boronate esters The present invention relates to optically active boronate derivatives which are useful as intermediates for the synthesis of HMG-CoA enzyme inhibitors such as atorvastatin, cerivastatin, rosuvastatin, pitavastatin, and fluvastatin. ... 01/26/06 - 20060019927 - Anti-viral uses of borinic acid complexes Compositions and methods of use of borinic acid complexes, especially hydroxyquinoline, imidazole and picolinic acid derivatives, as anti-viral agents as well as therapeutic agents for the treatment of diseases caused by viruses are described. ... 01/19/06 - 20060014723 - Anti-parasitic uses of borinic acid complexes Compositions and methods of use of borinic acid complexes, especially hydroxyquinoline, imidazole and picolinic acid derivatives as anti-parasitic agents as well as therapeutic agents for the treatment of diseases caused by parasite are described. ... 01/12/06 - 20060009422 - Boron-containing compounds and methods of use Methods of treating and/or preventing surface infections, such as acne, in an animal, such as a human being, using antibiotics incorporating borinic acid complexes, especially picolinic acid derivatives, are disclosed, along with compositions of these antibiotics. ... 12/29/05 - 20050288253 - Boronic acid salts Salts of a peptide boronic acid drug, for example of Cbz-(R)-Phe-(S)-Pro-(R)-Mpg-B(OH)2. The counter-ion to the boronate may be an alkali metal or derived from a strongly basic organic nitrogen-containing compound. ... 12/22/05 - 20050282780 - Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding Compounds, compositions and methods are provided for stabilizing transthyretin and for treating, preventing, or ameliorating one or more symptoms of transthyretin mediated diseases. In one embodiment, the compounds are benzoxazoles and related compounds. ... 12/22/05 - 20050282779 - Boron complexation strategy for use in manipulating 1-acyldipyrromethanes A method of making a metal complex comprises combining a 1-monoacyldipyrromethane with a compound of the formula R1R2MX, wherein M is boron, R1 and R2 are each independently organic substituents; and X is an anion leaving group; to produce a metal complex of the formula DMR1R2 wherein DH is a ... 12/22/05 - 20050282778 - Boron complexation strategy for use in manipulating 1-acyldipyrromethanes A method of making a metal complex comprises combining a 1-monoacyldipyrromethane with a compound of the formula R1R2MX, wherein M is boron, R1 and R2 are each independently organic substituents; and X is an anion leaving group; to produce a metal complex of the formula DMR1R2 wherein DH is a ... 12/08/05 - 20050272704 - Compounds, compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding Compounds, compositions and methods are provided for stabilizing transthyretin and for treating, preventing, or ameliorating one or more symptoms of transthyretin mediated diseases. In one embodiment, the compounds are biphenyls and related compounds. ... 12/08/05 - 20050272703 - Anti-tumor agents A method for treating subjects with abnormal cell proliferation is provided. The method involves administering to subjects in need of such treatment an effective amount of an agent of Formula I, to inhibit cell proliferation such as that associated with tumor growth and metastasis. A method for inhibiting angiogenesis in ... 12/08/05 - 20050272702 - Coupling process for generating reactive boron-containing derivatives of n-substituted pyrrole-2-carbonitriles to produce biaryls A convenient preparation of boron-containing compounds, borate salts, pyrrolecarbonitrile boron-containing compounds, N-substituted-pyrrole-2-carbonitrile boron-containing compounds, and derivatives thereof is provided. The present invention also provides for the use of these boron-containing compounds and derivatives thereof in coupling reactions to provide bi-aryl compounds. ... 12/01/05 - 20050267071 - Inhibitors of coronavirus protease and methods of use thereof This invention provides organic boron-containing compounds, compositions thereof, and methods of using such compounds and compositions for inhibiting coronavirus protease(s) and for treating infections. ... 11/03/05 - 20050245486 - Modified psma ligands and uses related thereto The instant invention provides reagents and methods for diagnosis, detection and treatment of cancers (for example, prostate cancers). In particular, the invention provides methods to generate various functionalized PSMA ligands, and their uses in diagnosis, detection, imaging, and treatment of prostate cancers, especially those overexpressing PSMA. ... 10/27/05 - 20050239750 - Hypoallergenic metal amino acid chelates and metal amino acid chelate-containing compositions Hypoallergenic metal amino acid chelate compositions, hypoallergenic formulations containing hypoallergenic metal amino acid chelates, methods of preparing hypoallergenic metal amino acid chelate, and methods of administering hypoallergenic metal amino acid chelates are provided. Specifically, the present invention provides metal amino acid chelates that are substantially free of allergens such that ... 09/22/05 - 20050209193 - Method for enhanced photodynamic therapy A method for treating a dermatopathological skin region or region of skin free of dermatopathology. In one embodiment of the invention, a method is disclosed wherein an amount of at least one photodynamic agent is applied to the skin region and photodynamic therapy (PDT) and radio frequency (RF) are applied. ... 08/25/05 - 20050187190 - Autoinducer-2 compounds as immunomodulatory agents The present method relates to modulating the mammalian inflammatory response using the bacterial autoinducer-2 and analogs and agonists thereof. In particular, the invention provides for ameliorating or reducing inflammation in inflammatory diseases and conditions associated with production of IL-1 and IL-6. ... 08/11/05 - 20050176683 - Methodology for preparing combinatorial libraries based upon a bicyclic scaffold The present invention relates to tetrahydro-pyrrolo[1,2-a]imidazole-2,5-dione derivative compounds, hexahydro-pyrrolo[1,2-a]pyrimidine-2,6-dione derivative compounds, and combinatorial libraries comprising such compounds. The present invention also relates to methods of preparing such compounds. The methods first involve providing a functionalized resin solid support. Next, the functionalized resin solid support is reacted with amino acids under ... 06/23/05 - 20050137169 - Vinca derivatives The present invention relates to derivatives of vinca alkaloids. Pharmaceutical compositions containing these compounds as well as processes of preparation and treatment of various conditions are also disclosed. ... 06/09/05 - 20050124580 - Beta-lactamase inhibitors and methods of use thereof The invention provides novel non-β-lactam inhibitors of β-lactamases. In particular, the invention provides boronic acid-based compounds set forth in the specification. These compounds may be used with β-lactam antibiotics to bacterial infection, particularly, β-lactam-antibiotic-resistant bacterial infections. These compounds are also antibacterial agents by themselves. The invention further provides methods of ... 06/02/05 - 20050119226 - Methods for synthesizing organoboronic compounds and products thereof Organoboronic acids, for example Cbz-(R)-Phe-(S)-Pro-(R)-Mpg-B(OH)2, are made by hydrolysing their diethanolamine adducts under conditions which avoid substantial C—B bond breakage. The product acids are substantially free of degradation product derived from cleavage of the C—B bond thereof. The acids are used to make base addition salts thereof. The salts are ... ### FreshPatents.com Support |